NASDAQ$LYEL
Lyell Immunopharma Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Lyell Immunopharma reported financial results for the third quarter of 2021 and provided business highlights.
Lyell Immunopharma reported a net loss of $48.9 million for the third quarter of 2021, compared to a net loss of $35.7 million for the same period in 2020. The company's cash and investments were $936.4 million as of September 30, 2021.
- Advanced multi-modality pipeline remains on track.
- Preparing to initiate multiple clinical trials incorporating two platforms.
- Cash and investments of $936.4 million as of September 30, 2021.
- Plan to submit four INDs by the end of 2022.
Headline financials
Revenue & EPS history
Lyell Immunopharma · Revenue · Quarterly
$2.76M
Forward guidance
Lyell anticipates progress in business plans, business strategy and planned clinical trials, plans to submit four INDs, potential clinical benefits and therapeutic potential of Lyell’s product candidates.
Tailwinds
- Lyell’s anticipated progress.
- Lyell’s business plans
- Lyell’s business strategy
- Lyell’s planned clinical trials
- Potential clinical benefits and therapeutic potential of Lyell’s product candidates
Headwinds
- Effects of the evolving COVID-19 pandemic
- Lyell’s ability to submit planned INDs on the anticipated timing or at all
- Initiation of planned clinical trials and enrollment of patients in its future clinical trials
- Lyell’s ability to manufacture and supply its product candidates for its future clinical trials
- The preclinical profiles of Lyell’s product candidates not translating in clinical trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.5%
Avg return
Earnings day
-4.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
73%
16 / 22 earnings
Positive
+20.3%
Q4 2024
Best reaction
-18.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -7.0% | -42.1% | |
| Q4 2025 | +2.5% | -19.0% | -9.6% | |
| Q3 2025 | -1.3% | +1.7% | +95.5% | |
| Q1 2025 | +4.6% | +2.0% | +21.1% | |
| Q4 2024 | +20.3% | +15.5% | -10.3% | |
| Q3 2024 | -17.6% | -21.3% | -38.9% | |
| Q2 2024 | +1.4% | -8.1% | -20.9% | |
| Q1 2024 | +7.6% | +4.2% | +13.6% | |
| Q4 2023 | +2.5% | -8.6% | -21.8% | |
| Q3 2023 | +6.8% | -24.8% | -11.8% | |
| Q2 2023 | +1.5% | -1.9% | -16.8% | |
| Q1 2023 | +6.9% | +6.5% | +50.9% | |
| Q4 2022 | +9.6% | +1.4% | -1.8% | |
| Q3 2022 | -18.3% | -17.0% | -28.8% | |
| Q2 2022 | +16.3% | +20.2% | +10.1% | |
| Q1 2021 | -12.4% | -22.8% | +1.5% | |
| Q1 2022 | -12.4% | -22.8% | +1.5% | |
| Q4 2019 | +6.1% | +6.1% | +1.6% | |
| Q4 2021 | +6.1% | +6.1% | +1.6% | |
| Q3 2021 | -4.1% | -3.6% | -18.8% | |
| Q4 2020 | +2.8% | +2.2% | +24.6% | |
| Q2 2021 | +2.8% | +2.2% | +24.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro